IP Library Granted Patent US 10,513,488
Granted Patent B2
US 10,513,488 · App. 15/472,779 · Granted Dec 24, 2019

Methods of manufacturing benzoquinoline compounds

Inventor: Chengzhi Zhang (San Diego, CA)
Assignee: AUSPEX PHARMACEUTICALS, INC.
C07C231/12C07B59/001C07B59/002C07C221/00C07C231/02C07D217/04C07D455/06C07B2200/05
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,513,488
App. No.
15/472,779
Granted
Dec 24, 2019
Kind
B2
Abstract

The present invention relates to new methods of manufacturing benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), and intermediates thereof.

Claims (46)

1. A process of preparing a racemic mixture of (RR,SS)-d 6 -tetrabenazine

(RR, SS)-d 6 -tetrabenazine

wherein the deuterium enrichment of the (RR, SS)-d 6 -tetrabenazine is no less than about 10%, comprising:

reacting d 6 -6,7-dimethoxy-3,4-dihydroisoquinoline, or a salt thereof:

d 6 -6,7-dimethoxy-3,4-dihydroisoquinoline

with a salt of 2-acetyl-N,N,N,4-tetramethyl-1-pentanaminium:

wherein X is halogen, alkyl sulfate, alkyl sulfonate, halosulfonate, perhaloalkyl sulfonate, aryl sulfonate, alkylaryl sulfonate, dialkyloxonium, alkylphosphate, or alkyl carbonate;

and an optional base;

in the presence of a solvent mixture that is a combination of water and an alcohol that is methanol or ethanol;

for a period of time and at a temperature sufficient to produce the (RR,SS)-d 6 -tetrabenazine having a diastereomeric purity of at least 99%, based on high performance liquid chromatography.

2. The process of claim 1 , wherein the solvent mixture is a combination of methanol and water.

3. The process of claim 2 , wherein the ratio of methanol:water is about 5:1 to about 1:1.

4. The process of claim 2 , wherein the ratio of methanol:water is about 3:1.

5. The process of claim 2 , wherein the ratio of methanol:water is about 1:1.

6. The process of claim 1 , wherein the solvent mixture is a combination of ethanol and water.

7. The process of claim 1 , wherein the d 6 -6,7-dimethoxy-3,4-dihydroisoquinoline is a salt form of d 6 -6,7-dimethoxy-3,4-dihydroisoquinoline.

8. The process of claim 7 , wherein the salt form of d 6 -6,7-dimethoxy-3,4-dihydroisoquinoline is d 6 -6,7-dimethoxy-3,4-dihydroisoquinoline hydrochloride.

9. The process of claim 8 , wherein the process is carried out in the presence of a base.

10. The process of claim 9 , wherein the base is K 2 CO 3 .

11. The process of claim 1 , wherein X is halogen.

12. The process of claim 11 , wherein the halogen is iodide.

13. The process of claim 1 , wherein the period of time is about 24 hours to about 63 hours.

14. The process of claim 1 , wherein the temperature is about 40° C. to about 60° C.

15. The process of claim 1 , wherein the diastereomeric purity is at least 99.1%.

16. The process of claim 1 , wherein the diastereomeric purity is at least 99.2%.

17. The process of claim 1 , wherein the diastereomeric purity is at least 99.5%.

18. The process of claim 1 , wherein the diastereomeric purity is at least 99.6%.

19. The process of claim 1 , wherein the diastereomeric purity is at least 99.9%.

20. The process of claim 1 , wherein the deuterium enrichment of the (RR,SS)-d 6 -tetrabenazine is no less than about 50%.

21. The process of claim 1 , wherein the deuterium enrichment of the (RR,SS)-d 6 -tetrabenazine is no less than about 90%.

22. The process of claim 1 , wherein the deuterium enrichment of the (RR,SS)-d 6 -tetrabenazine is no less than about 98%.

23. The process of claim 4 , wherein a salt form of d 6 -6,7-dimethoxy-3,4-dihydroisoquinoline is reacted and the salt form is d 6 -6,7-dimethoxy-3,4-dihydroisoquinoline hydrochloride.

24. The process of claim 23 , wherein the process is carried out in the presence of K 2 CO 3.

25. The process of claim 24 , wherein Xis halogen.

26. The process of claim 25 , wherein the halogen is iodide.

27. The process of claim 26 , wherein the diastereomeric purity is at least 99.1%.

28. The process of claim 4 , wherein Xis halogen.

29. The process of claim 28 , wherein the halogen is iodide.

30. The process of claim 4 , wherein the deuterium enrichment of the (RR,SS)-d 6 -tetrabenazine is no less than about 50%.

31. The process of claim 4 , wherein the deuterium enrichment of the (RR,SS)-d 6 -tetrabenazine is no less than about 90%.

32. The process of claim 4 , wherein the deuterium enrichment of the (RR,SS)-d 6 -tetrabenazine is no less than about 98%.

33. The process of claim 23 , wherein the deuterium enrichment of the (RR,SS)-d 6 -tetrabenazine is no less than about 50%.

34. The process of claim 23 , wherein the deuterium enrichment of the (RR,SS)-d 6 -tetrabenazine is no less than about 90%.

35. The process of claim 23 , wherein the deuterium enrichment of the (RR,SS)-d 6 -tetrabenazine is no less than about 98%.

36. The process of claim 4 , wherein a salt form of d 6 -6,7-dimethoxy-3,4-dihydroisoquinoline is reacted and the salt form is d 6 -6,7-dimethoxy-3,4-dihydroisoquinoline hydrochloride, X is iodide, and the diastereomeric purity is at least 99.1.

37. The process of claim 36 , wherein the process is carried out in the presence of K 2 CO 3.

Assignments (2)
CHANGE OF NAME Recorded Oct 13, 2025
From: AUSPEX PHARMACEUTICALS, INC.
To: AUSPEX PHARMACEUTICALS LLC
Reel/Frame 073081/0059 →
CHANGE OF ASSIGNEE ADDRESS Recorded Feb 2, 2021
From: AUSPEX PHARMACEUTICALS, INC.
To: AUSPEX PHARMACEUTICALS, INC.
Reel/Frame 055193/0866 →
Continuity (3)
Continuation 14551909 · Nov 24, 2014
Provisional Application 61911214 · Dec 3, 2013
Related Publication 20170197957A1 · Jul 13, 2017